US health secretary Robert F. Kennedy Jr. is pushing to deregulate peptides, a move intended to simplify the process of purchasing these drugs. However, the proposal faces criticism for failing to provide consumers with what they arguably need most: empirical evidence of safety and efficacy.
While deregulation may ease access, critics suggest it does little to verify that these substances actually work. The shift in policy highlights a growing tension between market accessibility and the clinical oversight necessary to ensure public health.
Read the full story at Business of Fashion (subscription).
Source · Business of Fashion
